Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.16 USD
+0.62 (1.74%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $36.14 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Collegium Pharmaceutical, Inc. has a PEG ratio of 0.30 compared to the Medical - Drugs industry's PEG ratio of 1.34.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
COLL 36.16 +0.62(1.74%)
Will COLL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?
Other News for COLL
Lower Bollinger Band Walk appears for COLL after 0.22% move
Is COLL poised for gains? Crossed Above 50 Day Moving Average shows up after advancing 2.0%
COLL Fell Below 50 Day Moving Average on September 15
COLL Fell Below 20 Day Moving Average on September 12
COLL Crossed Above 20 Day Moving Average on September 11